1. Catalog
  2. Guideline Update: Adult Liver Transplantation-Cand ...
Guideline Update: Adult Liver Transplantation-Candidate Examination
Create Account
Availability
On-Demand
Cost
Member: $0.00
Non-Member: $25.00
Patient: $0.00
Associate: $0.00
Student: $0.00
Early Career: $0.00
Industry Rep: $25.00
Credit Offered
0.5 AMA PRA Category 1 Credit
  • Description
  • Learning Objectives
  • Accreditation Information
  • Faculty and Disclosures
  • Privacy Policy
Liver transplantation (LT), first performed in 1963, has evolved from an experimental procedure to a life-saving therapy, with over 10,000 transplants conducted annually in the United States by 2023. This growth reflects major advances in immunosuppression, surgical techniques, donor management, and pre- and post-transplant care. LT serves as an essential treatment for patients with acute or chronic liver failure and certain malignancies or metabolic diseases unresponsive to medical therapy, with evaluation tailored to each patient’s illness severity, comorbidities, and social factors. Ethical considerations, particularly fairness in organ allocation and avoidance of judgments about social worth, remain central to the field. The latest AASLD guideline provides updated, evidence-based recommendations to ensure transparent, consistent evaluation updated, evidence-based recommendations to ensure transparent, consistent evaluation and selection practices across transplant centers.

COPYRIGHT: All faculty in this activity have given their permission for publication ©2025 AASLD.
Upon completion of this activity, participants should be able to:

  • Describe the evolution and and current scope of liver transplantation
  • Analyze clinical and ethical criteria for candidate evaluation
  • Evaluate strategies for maintaining fairness and transparency in organ allocation
The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this enduring material activity for a maximum of #.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date: November 25, 2025
Expiration Date: November 25, 2027

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Catherine Luccero. MD
Nothing to Disclose

Lorna Dove, MD, MPH
Nothing to Disclose

Michael Lucey, MD, FAASLD  
Scientific Consultant/Advisor: Novartis
Grant/Research Support: Pharma Solutions, Intercept, Exact Sciences

Powered By